Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Consensus Recommendation of “Hold” from Brokerages

Dynavax Technologies Corporation (NASDAQ:DVAX) has earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $24.3333.

DVAX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. JMP Securities reissued a “market outperform” rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Blair William & Co. IL lifted its stake in Dynavax Technologies by 0.3% in the 2nd quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock valued at $22,614,000 after buying an additional 6,940 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Dynavax Technologies by 33.8% during the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company’s stock valued at $28,633,000 after acquiring an additional 558,046 shares during the last quarter. Marshall Wace LLP increased its position in Dynavax Technologies by 12.2% during the 3rd quarter. Marshall Wace LLP now owns 2,036,003 shares of the biopharmaceutical company’s stock worth $20,218,000 after purchasing an additional 221,069 shares in the last quarter. Bank of America Corp DE raised its stake in Dynavax Technologies by 25.7% in the 3rd quarter. Bank of America Corp DE now owns 1,458,087 shares of the biopharmaceutical company’s stock valued at $14,479,000 after purchasing an additional 298,106 shares during the last quarter. Finally, Glenmede Investment Management LP lifted its holdings in Dynavax Technologies by 23.8% in the 3rd quarter. Glenmede Investment Management LP now owns 1,264,369 shares of the biopharmaceutical company’s stock valued at $12,555,000 after purchasing an additional 243,240 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of DVAX opened at $11.18 on Friday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -24.30 and a beta of 1.09. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $14.63. The firm has a 50-day simple moving average of $10.27 and a 200-day simple moving average of $10.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. On average, equities research analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.